GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mabpharm 2181.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.48

—

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥629.4m

FY2017FY2025

Net income

CN¥55.7m

FY2017FY2025

Free cash flow

−CN¥23.2m

FY2017FY2025

Shareholders' equity

CN¥157.4m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueCN¥629.4mCN¥220.8mCN¥74.5mCN¥47.8mCN¥70.9m—CN¥14.1mCN¥23.9mCN¥4.7m
Research and developmentCN¥49.3mCN¥64.3mCN¥105.4mCN¥126.5mCN¥225.4mCN¥120.4mCN¥134.2mCN¥89.0mCN¥21.6m
Operating incomeCN¥4.7m−CN¥100.8m−CN¥170.8m−CN¥193.5m−CN¥254.4m−CN¥186.2m−CN¥198.8m−CN¥119.7m−CN¥44.4m
Net incomeCN¥55.7m−CN¥109.4m−CN¥179.0m−CN¥180.1m−CN¥249.5m−CN¥188.6m−CN¥210.2m−CN¥124.9m−CN¥31.1m
Diluted earnings per share0.01-0.03-0.04-0.04-0.06-0.05-0.05-0.04-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsCN¥1.15bnCN¥869.0mCN¥885.0mCN¥784.6mCN¥769.5mCN¥1.16bnCN¥1.40bnCN¥473.2mCN¥289.1m
Cash and short-term investmentsCN¥109.3mCN¥76.4mCN¥148.2mCN¥41.6mCN¥69.7mCN¥484.8mCN¥767.9mCN¥198.2mCN¥76.4m
Total liabilitiesCN¥996.6mCN¥792.9mCN¥709.7mCN¥441.7mCN¥254.8mCN¥281.6mCN¥342.8mCN¥223.7mCN¥135.9m
DebtCN¥326.9mCN¥250.6mCN¥222.4mCN¥108.0mCN¥39.7mCN¥40.3mCN¥214.3mCN¥105.0mCN¥75.0m
Shareholders' equityCN¥157.4mCN¥76.0mCN¥175.3mCN¥342.9mCN¥514.8mCN¥881.5mCN¥1.05bnCN¥249.6mCN¥99.8m
Shares outstanding4,123m4,124m4,124m4,124m4,124m4,124m4,124m2,974m4,124m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operationsCN¥80.8m−CN¥3.5mCN¥49.1m−CN¥48.6m−CN¥170.6m−CN¥147.2m−CN¥136.6m−CN¥61.9m−CN¥65.1m
Capital spending−CN¥104.0m−CN¥50.9m−CN¥16.3m−CN¥107.0m−CN¥127.1m−CN¥197.2m−CN¥113.6m−CN¥90.9m−CN¥13.1m
Free cash flow−CN¥23.2m−CN¥54.4mCN¥32.8m−CN¥155.6m−CN¥297.7m−CN¥344.5m−CN¥250.2m−CN¥152.8m−CN¥78.3m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥398.4mCN¥365.7mCN¥274.2mCN¥128.0mCN¥92.8mCN¥36.9mCN¥37.6mCN¥23.1m
Operating incomeCN¥34.7mCN¥1.9mCN¥2.9m−CN¥22.9m−CN¥79.5m−CN¥90.2m−CN¥82.6m−CN¥88.0m
Net incomeCN¥31.4mCN¥53.3mCN¥2.9m−CN¥26.0m−CN¥83.4m−CN¥93.5m−CN¥85.5m−CN¥80.4m
Diluted earnings per share0.010.010.00-0.01-0.02-0.02-0.02-0.02
Cash from operationsCN¥61.0mCN¥37.0mCN¥43.0mCN¥51.0m−CN¥54.0mCN¥77.0m−CN¥28.0m−CN¥39.0m
Capital spending−CN¥13.0m−CN¥67.0m−CN¥36.0m−CN¥11.0m−CN¥10.0m−CN¥10.0m−CN¥6.0m−CN¥23.0m
Free cash flowCN¥48.0m−CN¥30.0mCN¥7.0mCN¥40.0m−CN¥64.0mCN¥67.0m−CN¥34.0m−CN¥62.0m
Total assetsCN¥1.17bnCN¥1.15bnCN¥1.07bnCN¥869.0mCN¥809.3mCN¥885.0mCN¥772.1mCN¥784.6m
Cash and short-term investmentsCN¥93.3mCN¥109.3mCN¥94.2mCN¥76.4mCN¥63.3mCN¥148.2mCN¥19.8mCN¥41.6m
DebtCN¥184.9mCN¥326.7mCN¥305.0mCN¥250.6mCN¥208.3mCN¥222.4mCN¥126.1mCN¥120.8m
Shareholders' equityCN¥193.8mCN¥157.4mCN¥98.9mCN¥76.0mCN¥98.5mCN¥175.3mCN¥262.2mCN¥342.9m

Financial ratios

Data as of 31 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin0.7%-46.3%-229.2%-364.2%-349.1%—-1330.1%—
Net margin8.8%-49.5%-240.2%-376.7%-352.0%—-1493.7%—
Return on equity35.4%-143.9%-102.1%-52.5%-48.5%-21.4%——
Return on assets4.8%-12.6%-20.2%-23.0%-32.4%-16.2%——
Free cash flow yield10.3%3.1%4.3%3.8%-2.8%2.8%——
Revenue growth143.7%196.3%55.9%-32.5%——-41.2%410.2%
Earnings growth-143.5%-38.9%-0.6%-27.8%54.7%-10.3%——
Current ratio0.81x1.17x1.08x1.07x1.05x2.81x——
Debt to equity1.91x2.95x1.11x0.28x0.02x0.01x——
Equity ratio13.6%8.8%19.8%43.7%66.9%75.8%——
Interest coverage0.44x-11.34x-20.86x-28.33x-120.41x-47.24x——
R&D as a share of sales7.8%29.1%141.4%264.5%318.0%—953.5%—
Buybacks as a share of market value0.0%0.0%0.0%0.0%0.0%0.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue136.1%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings32.1-9.1-9.2-8.6-14.3-19.9-19.5
Price to sales2.84.522.132.550.4—291.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.